摘要
文章制备了芳基钌(Ⅱ)配合物[Ru(η^(6)-伞花烃)(2-氨甲基吡啶-N,N)Cl]PF_(6),利用FT-IR和NMR光谱法等技术进行了结构表征,采用MTT法测定其体外对人癌细胞系HepG-2(HCC)、A549(lung)、Hela(cervical)、MCF-7(breast)的生长抑制作用,以临床用药顺铂为对照。结果表明该化合物对HepG-2、A549和HeLa的抑制作用呈剂量依赖关系,浓度在100μg/mL左右时,抑制效果与顺铂相当;对MCF-7(breast)几乎无抑制作用。以上说明配合物1具有一定的抗肿瘤作用,值得后期进一步研究。
A Ru(Ⅱ)-arene complex of the type[Ru(η^(6)-p-cymene)(2-picolylamine-N,N)Cl]PF_(6)was synthesized and characterized by FT-IR and NMR spectroscopy.Cytotoxicities against 4 human cancer cell lines(HepG-2,A549,Hela,MCF-7)in vitro were measured by MTT method and compared with the clinically used anticancer drug cisplatin.The assay revealed that the inhibitory effect of the compound 1 on HepG-2,A549 and HeLa was dose-dependent respectively,and showed comparable effect compared with cisplatin when the concentration was about 100μg/mL.It showed almost no inhibitory effect on MCF-7(breast).These results indicated that compound 1 had certain antitumor effect and was worthy of further study in the later period.
作者
邵长兴
余群英
SHAO Chang-xing;YU Qun-ying(School of Pharmacy and Life Science,Jiujiang University,Jiangxi Jiujiang 332005,China)
出处
《广州化工》
CAS
2021年第7期47-48,74,共3页
GuangZhou Chemical Industry
基金
江西省教育厅科学技术研究项目(GJJ180907)
江西省卫生健康科委科技计划项目(202131075)。
关键词
钌配合物
双齿配体
抗癌活性
顺铂
2-氨甲基吡啶
ruthenium complex
bidentate ligand
anticancer activity
cisplatin
2-picolylamine
